J&J’s Esketamine: A Model “Breakthrough” Program For US FDA

 
• By Michael McCaughan
  
Esketamine advisory committee discussion showed how J&J and FDA worked hand-in-hand to craft a unique development program for a unique therapy.

More from Review Pathways

More from Pathways & Standards